Recent posts

When Resolving Minor Differences in Protein Therapeutics Can Have a Major Impact

By November 6, 2018

Scientists from Waters and Pfizer collaborated to take on the challenge of engineering a novel reversed-phase LC column for high-throughput separations with enhanced resolution, selectivity, and recovery of target mAbs and ADCs.

Categories: Columns, Technologies
Tags: , , ,

I Resolve to Get Better mAb Separations

By August 8, 2018

We listened and learned how scientists separate mAbs and ADCs; then we designed a novel column for LC-MS bioseparations A critical step toward the prolific and successful use of monoclonal antibodies (mAb) as biotherapeutics occurred… Read more >

Categories: Columns
Tags: , , , , , , , ,

How to improve analytical method transfers for biotherapeutics

By May 21, 2018

“Assuming continuous improvement is a worthy goal, there is every reason to improve validated chromatographic methods if you’re working with the right instrument technology,” says Eric Grumbach of Waters. See what that means for developing and transferring methods for biologic drugs.

Categories: Pharmaceutical
Tags: , , , , , , , , , , ,

Setting a New Standard for Reserved-Phase Separations of Monoclonal Antibodies and Antibody Drug Conjugates

By May 15, 2018

A new approach to stationary phase chemistry for reversed-phase LC analysis of proteins, including monoclonal antibodies and antibody drug conjugates, delivers higher fidelity data especially for MS-based peak identification.

Categories: Columns
Tags: , , , , , , , , ,